NEW DELHI: Stepping up its overseas expansion, Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan. "Increasingly, our focus is to expand not only in the developed markets but also in emerging ones. Recently we have started exporting our anti-cancer drugs to Pakistan," Dabur Pharma additional director and non-executive chairman Mohit Burman said.The move follows the Pakistan government allowing imports of anti-cancer drugs from India since last month.
The country's health ministry has already granted permission to two companies — Atco Pharma and AJ Mirza Pharma to import from Dabur Pharma.
Besides Pakistan, in the first quarter of the fiscal Dabur Pharma had also started dispatches to Turkmenistan from its dosage form manufacturing unit at Baddi in Himachal Pradesh. With the next generation of Burmans being given more responsibility of running the Dabur empire, its pharma division is also on the prowl for acquisitions abroad."Similar acquisitions like the one we did in Thailand are a possibility in key markets, which we have identified," Burman said. Dabur Pharma had acquired sales and distribution network of Biosciences and the company's drug Intaxel became the first ever generic oncology drug to cross 100 million Baht sales mark in the country.